文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

非心肌细胞在糖尿病心肌病发展中的作用及 FGF21 的保护作用：当前认识。

The role of nonmyocardial cells in the development of diabetic cardiomyopathy and the protective effects of FGF21: a current understanding.

机构信息

School of Basic Medical Sciences, Southwest Medical University, Luzhou, 646000, Sichuan, China.

Department of Neurosurgery, the Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, China.

出版信息

Cell Commun Signal. 2024 Sep 26;22(1):446. doi: 10.1186/s12964-024-01842-0.

DOI:10.1186/s12964-024-01842-0
PMID:39327594
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11426003/
Abstract

Diabetic cardiomyopathy (DCM) represents a unique myocardial disease originating from diabetic metabolic disturbances that is characterized by myocardial fibrosis and diastolic dysfunction. While recent research regarding the pathogenesis and treatment of DCM has focused primarily on myocardial cells, nonmyocardial cells-including fibroblasts, vascular smooth muscle cells (VSMCs), endothelial cells (ECs), and immune cells-also contribute significantly to the pathogenesis of DCM. Among various therapeutic targets, fibroblast growth factor 21 (FGF21) has been identified as a promising agent because of its cardioprotective effects that extend to nonmyocardial cells. In this review, we aim to elucidate the role of nonmyocardial cells in DCM and underscore the potential of FGF21 as a therapeutic strategy for these cells.

摘要

糖尿病心肌病（DCM）代表了一种源自糖尿病代谢紊乱的独特心肌疾病，其特征是心肌纤维化和舒张功能障碍。虽然最近关于 DCM 的发病机制和治疗的研究主要集中在心肌细胞上，但非心肌细胞——包括成纤维细胞、血管平滑肌细胞（VSMCs）、内皮细胞（ECs）和免疫细胞——也对 DCM 的发病机制有重要贡献。在各种治疗靶点中，成纤维细胞生长因子 21（FGF21）已被确定为一种有前途的药物，因为它对非心肌细胞的心脏保护作用。在这篇综述中，我们旨在阐明非心肌细胞在 DCM 中的作用，并强调 FGF21 作为这些细胞治疗策略的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2799/11426003/c56e30d7af2a/12964_2024_1842_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2799/11426003/cef28bf2681c/12964_2024_1842_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2799/11426003/c7e9cecfd841/12964_2024_1842_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2799/11426003/8b3a8d13f0e2/12964_2024_1842_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2799/11426003/6987817fddea/12964_2024_1842_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2799/11426003/c56e30d7af2a/12964_2024_1842_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2799/11426003/cef28bf2681c/12964_2024_1842_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2799/11426003/c7e9cecfd841/12964_2024_1842_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2799/11426003/8b3a8d13f0e2/12964_2024_1842_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2799/11426003/6987817fddea/12964_2024_1842_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2799/11426003/c56e30d7af2a/12964_2024_1842_Fig5_HTML.jpg

相似文献

[1]
The role of nonmyocardial cells in the development of diabetic cardiomyopathy and the protective effects of FGF21: a current understanding.

Cell Commun Signal. 2024-9-26

[2]
Single-cell insights: pioneering an integrated atlas of chromatin accessibility and transcriptomic landscapes in diabetic cardiomyopathy.

Cardiovasc Diabetol. 2024-4-25

[3]
FGF21 deletion exacerbates diabetic cardiomyopathy by aggravating cardiac lipid accumulation.

J Cell Mol Med. 2015-7

[4]
Ultrasound-assisted CF-filled PLGA nanobubbles for enhanced FGF21 delivery and improved prophylactic treatment of diabetic cardiomyopathy.

Acta Biomater. 2021-8

[5]
FGF21-Sirtuin 3 Axis Confers the Protective Effects of Exercise Against Diabetic Cardiomyopathy by Governing Mitochondrial Integrity.

Circulation. 2022-11-15

[6]
A review of fibroblast growth factor 21 in diabetic cardiomyopathy.

Heart Fail Rev. 2019-11

[7]
Synthetic prostacyclin agonist, ONO1301, enhances endogenous myocardial repair in a hamster model of dilated cardiomyopathy: a promising regenerative therapy for the failing heart.

J Thorac Cardiovasc Surg. 2013-12

[8]
IL-37 ameliorates myocardial fibrosis by regulating mtDNA-enriched vesicle release in diabetic cardiomyopathy mice.

J Transl Med. 2024-5-24

[9]
FGF21 ameliorates diabetic cardiomyopathy by activating the AMPK-paraoxonase 1 signaling axis in mice.

Clin Sci (Lond). 2017-7-7

[10]
Biological Functions and Clinical Prospects of Extracellular Non-Coding RNAs in Diabetic Cardiomyopathy: an Updated Review.

J Cardiovasc Transl Res. 2022-6

引用本文的文献

[1]
New insights into FGF21 alleviates diabetic cardiomyopathy by suppressing ferroptosis: a commentary.

Cardiovasc Diabetol. 2024-11-26

本文引用的文献

[1]
The role of FGF-21 in promoting diabetic wound healing by modulating high glucose-induced inflammation.

Heliyon. 2024-4-28

[2]
Interleukin-1β polarization in M1 macrophage mediates myocardial fibrosis in diabetes.

Int Immunopharmacol. 2024-4-20

[3]
Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study.

Clin Gastroenterol Hepatol. 2025-1

[4]
High Glucose Levels Promote Switch to Synthetic Vascular Smooth Muscle Cells via Lactate/GPR81.

Cells. 2024-1-26

[5]
Dual delivery gene-activated scaffold directs fibroblast activity and keratinocyte epithelization.

APL Bioeng. 2024-1-26

[6]
FGF21 alleviates endothelial mitochondrial damage and prevents BBB from disruption after intracranial hemorrhage through a mechanism involving SIRT6.

Mol Med. 2023-12-4

[7]
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.

Lancet Gastroenterol Hepatol. 2023-12

[8]
Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy-confirmed nonalcoholic steatohepatitis.

Aliment Pharmacol Ther. 2023-11

[9]
Population Pharmacokinetics and Pharmacodynamics of Pegozafermin in Patients with Nonalcoholic Steatohepatitis.

Clin Pharmacol Ther. 2023-12

[10]
High glucose promotes macrophage M1 polarization through miR-32/Mef2d/cAMP signaling pathway.

Genes Dis. 2023-5-3

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索